These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 6800179)

  • 21. [Glycosaminoglycans of human thrombocytes in normal conditions, in chronic myeloid leukosis, myelofibrosis and polycythemia vera].
    Kharchenko MF
    Vopr Med Khim; 1973; 19(6):613-7. PubMed ID: 4277844
    [No Abstract]   [Full Text] [Related]  

  • 22. Spontaneous platelet aggregation in myeloproliferative disorders. A preliminary study.
    Barbui T; Battista R; Dini E
    Acta Haematol; 1973; 50(1):25-9. PubMed ID: 4200801
    [No Abstract]   [Full Text] [Related]  

  • 23. Studies on the phagocytic activity of neutrophilic leukocytes.
    Brandt L
    Scand J Haematol Suppl; 1967; 2():1-126. PubMed ID: 5243720
    [No Abstract]   [Full Text] [Related]  

  • 24. Platelet 5-hydroxytryptamine transport and storage in myeloproliferative disorders.
    Cortellazzo S; Viero P; Buczko W; Barbui T; de Gaetano G
    Scand J Haematol; 1985 Feb; 34(2):146-51. PubMed ID: 3856312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Platelets in the myeloproliferative syndrome.
    Weinfeld A; Branehög I; Kutti J
    Clin Haematol; 1975 Jun; 4(2):373-92. PubMed ID: 1102193
    [No Abstract]   [Full Text] [Related]  

  • 26. Plasma fibronectin in idiopathic myelofibrosis and related chronic myeloproliferative disorders.
    Hasselbalch H; Clemmensen I
    Scand J Clin Lab Invest; 1987 Sep; 47(5):429-33. PubMed ID: 3477850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vivo platelet release in myeloproliferative disorders.
    Ireland H; Lane DA; Wolff S; Foadi M
    Thromb Haemost; 1982 Aug; 48(1):41-5. PubMed ID: 6215739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Observations on the in vitro growth of peripheral leucocytes from patients with myeloproliferative disorders.
    Pegrum GD
    Br J Haematol; 1966 Nov; 12(6):689-96. PubMed ID: 5224278
    [No Abstract]   [Full Text] [Related]  

  • 29. Impaired conversion of exogenous arachidonic acid by platelets to thromboxane B2 and correction of that deficiency by interferon-alpha.
    Sinzinger H; Linkesch W; Ludwig H; Gisslinger H; O'Grady J; Peskar BA
    Prostaglandins; 1990 Oct; 40(4):351-60. PubMed ID: 2126385
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [On the existence of a myeloproliferative factor in patients with a myeloproliferative syndrome (author's transl)].
    Essers U; Nowak H
    Blut; 1979 Aug; 39(2):107-15. PubMed ID: 289427
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Megakaryocytes in cubital venous blood in patients with chronic myeloproliferative diseases.
    Tinggaard Pedersen N; Laursen B
    Scand J Haematol; 1983 Jan; 30(1):50-8. PubMed ID: 6573016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Secondary hyperuricemia in hemoblastosis].
    Richter R; Hermanny G; Hofer E; Stobbe H
    Dtsch Gesundheitsw; 1971 Nov; 26(45):2126-30. PubMed ID: 5145658
    [No Abstract]   [Full Text] [Related]  

  • 33. Hypocholesterolemia in myeloproliferative disorders.
    Spanos GA; Bajaj K; Rosner F
    Arch Intern Med; 1981 Jan; 141(1):137-8. PubMed ID: 6934710
    [No Abstract]   [Full Text] [Related]  

  • 34. [Hemostasis disorders with reduced activity of the von Willebrand factor in myeloproliferative syndromes].
    Leupin L; Beck EA; Furlan M; Bucher U
    Schweiz Med Wochenschr; 1983 May; 113(19):713-6. PubMed ID: 6603016
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phagocytosis in myeloproliferative disorders.
    Corberand J; LaHarrague P; De Larrard B; Nguyen F; Pris J
    Am J Clin Pathol; 1980 Sep; 74(3):301-5. PubMed ID: 6932175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Reduced glutathione (GSH) in erythrocytes in myeloproliferative diseases].
    Benöhr HC; Tigges FJ; Waller HD
    Verh Dtsch Ges Inn Med; 1973; 79():461-3. PubMed ID: 4790261
    [No Abstract]   [Full Text] [Related]  

  • 37. Abnormalities of epinephrine-induced platelet aggregation and adenine nucleotides in myeloproliferative disorders.
    Yamamoto K; Sekiguchi E; Takatani O
    Thromb Haemost; 1984 Dec; 52(3):292-6. PubMed ID: 6531753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Familial myeloproliferative syndromes. Study of 6 families and review of literature].
    Kaufman S; Brière J; Bernard J
    Nouv Rev Fr Hematol (1978); 1978 Apr; 20(1):1-15. PubMed ID: 353725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reticulated platelets are increased in chronic myeloproliferative disorders, pure erythrocytosis, reactive thrombocytosis and prior to hematopoietic reconstitution after intensive chemotherapy.
    Ryningen A; Apelseth T; Hausken T; Bruserud Ø
    Platelets; 2006 Aug; 17(5):296-302. PubMed ID: 16928601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biochemical and metabolic aspects of platelet dysfunction in chronic myeloproliferative disorders.
    Pareti FI; Gugliotta L; Mannucci L; Guarini A; Mannucci PM
    Thromb Haemost; 1982 Apr; 47(2):84-9. PubMed ID: 7101243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.